In vitro modulation of human, autoreactive MBP-specific CD4 + T-cell clones by cyclosporin A

J Neuroimmunol. 1997 Jun;76(1-2):91-9. doi: 10.1016/s0165-5728(97)00035-0.

Abstract

Cyclosporin A (CsA) is a potent immunosuppressant affecting many components of cellular and humoral immunity. Its main action probably results from inhibition of T-lymphocyte activation and interference with secretion of cytokines like IL-2, IL-4, IFN-gamma and TNF-alpha. Correspondingly, CsA has beneficial effects on the course of several autoimmune diseases thought to be mediated by T-lymphocytes, including a mild effect on multiple sclerosis. We exposed CD4 + cytotoxic T-lymphocytes specific for myelin basic protein, a putative target autoantigen in MS, to CsA in vitro, and determined the drug's effects on proliferation, expression of high affinity IL-2R, secretion of the proinflammatory cytokines IFN-gamma and TNF-alpha as well as on the secretion of the chemokines MIP-1 alpha and MIP-1 beta. In all instances, we observed a partial to complete inhibition. In contrast, the response of activated cells to IL-2 was resistant to CsA. Our observations are in line with results obtained in different experimental systems. The discrepancy between the profound inhibition of T-cells and the modest therapeutic effects on MS is discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4-Positive T-Lymphocytes / drug effects*
  • Clone Cells
  • Cyclosporine / pharmacology*
  • Cytokines / biosynthesis
  • Dose-Response Relationship, Drug
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Interleukin-2 / pharmacology
  • Lymphocyte Activation / drug effects
  • Myelin Basic Protein / immunology*

Substances

  • Cytokines
  • Immunosuppressive Agents
  • Interleukin-2
  • Myelin Basic Protein
  • Cyclosporine